Cytosorbents (CTSO) Investor presentation summary

Business and platform

• CytoSorb is a CE-mark-approved blood purification device in the EU, used to remove cytokines, bilirubin, myoglobin and selected blood thinners; it is not approved in the U.S. or Canada.

• Distributed in more than 70 countries, with 300,000+ human treatments; 2025 sales were $37.1M, including 67% critical care and 33% cardiac surgery revenue.

• Porous polymer beads capture and concentrate harmful substances; the platform has 20 issued U.S. patents and multiple patents issued or pending worldwide.

• Products are designed to work with existing hospital blood-pump infrastructure, including dialysis or CRRT, hemoperfusion, ECMO and cardiopulmonary bypass.

Commercial performance and cash

• Q2 2026 revenue was $9.6M, product gross margin was 73%, operating loss improved 27% and adjusted EBITDA improved 38%.

• Q2 2026 operating cash burn was ~$200K, excluding ~$200K of restructuring costs; cash, cash equivalents and restricted cash totaled $5.9M at quarter-end.

• Headcount was reduced 23% since September 2025; operating cash-flow breakeven remains targeted for 2H 2026.

• 2025 revenue by channel: 44% direct sales in Germany, 24% direct sales in other listed European markets and 32% distributors or partners.

DrugSorb-ATR

• Investigational device targeting removal of ticagrelor and DOACs during cardiac surgery; it has two FDA Breakthrough Device designations and is not approved in the U.S. or Canada.

• In the STAR-T trial, the primary efficacy endpoint was not met overall or in the CABG population; safety endpoint was met, and the CABG subgroup met a supplementary efficacy endpoint.

• In the prespecified CABG subgroup, major bleeding was 13.7% with treatment vs. 30.0% in controls; reported relative reduction was 57.7%, with NNT of 6.

• An ESC 2026 matched analysis of 587 urgent CABG patients found 37% lower relative BARC-4 severe bleeding with device use; NNT was 8, with no serious device-related adverse events reported.

• A new FDA De Novo submission is targeted for early 2027, with potential marketing approval in mid-2027; stated initial opportunity exceeds $300M and future opportunity is $1–2B.